UKHSA publishes a national influenza and COVID-19 surveillance report which summaries the information from the surveillance systems which are used to monitor influenza, COVID-19 and other seasonal respiratory viruses in England.

Additional figures based on these surveillance systems are included in this slide set.

The figures presented in this slide set are based on data from week 22 (between 29 May and 4 June 2023).
Corrections

An error was made at the data generation stage for the graph relating to Datamart RSV positivity (slide 15) and underlying data. The incorrect week values were included.

The main surveillance report was not affected.

The error has now been corrected (slide 15).
1) Confirmed COVID-19 episodes in England
2) Respiratory Datamart system (England)
3) Google search queries
4) Flu detector
5) Secondary Care surveillance
6) SARS-CoV-2 Whole Genome Sequencing (WGS) coverage, England
Confirmed COVID-19 episodes in England
Confirmed COVID-19 episodes in England

Data Information

- From the week 32 report onwards, case rates have been updated to use the latest ONS population estimates for mid-2020. Previously case rates were calculated using the mid-2019 population estimates.

- From 11 January 2022 the requirement for confirmatory PCR testing in individuals who test positive using a lateral flow device was temporarily removed.

- Rates by ethnicity and IMD quantile will continue to be presented using the mid-2019 estimates, until the mid-2020 estimates become available.

- From 31 January 2022, UKHSA moved all COVID-19 case reporting in England to use a new episode-based definition which includes possible reinfections. Each infection episode is counted separately if there are at least 91 days between positive test results (PCR or LFD). Each infection episode begins with the earliest positive specimen date. Further information can be found on the UK COVID-19 dashboard.

- Since 1 April 2022, free universal symptomatic and asymptomatic testing for the general public in England is no longer available, as outlined in the plan for living with COVID-19. As such, there will be a reduction in the reporting of data obtained through Pillar 2 from April 2022 onwards. Data in this report should be interpreted in the context of this change to testing. Public health guidance remains in place for cases and their close contacts. Additionally, further changes in testing policy are in effect since 1 April 2023, which may affect case rates and positivity rates.
Seven-day rolling average PCR positivity (%) of confirmed COVID-19 cases tested by sex under Pillar 1
Weekly confirmed COVID-19 case rates by episode, per 100,000 population (Pillar 1), by UKHSA centres and sample week

[Graph showing weekly confirmed COVID-19 case rates by episode, per 100,000 population (Pillar 1), by UKHSA centres and sample week.]
Weekly incidence per 100,000 population by ethnicity (Pillar 1), England
Weekly COVID-19 episodes tested under Pillar 1, per 100,000 population by age group and region, weeks 13 to 22
Weekly COVID-19 episodes tested under Pillar 1, per 100,000 population by ethnicity and region, weeks 13 to 22
Weekly COVID-19 rate tested under Pillar 1, per 100,000 population by IMD quintile (1 being the most deprived and 5 being the least deprived)

*incidence rates have been calculated using the mid-2019 ONS population estimates
Respiratory Datamart system (England)
Respiratory DataMart weekly positivity (%) for influenza by age, England
Respiratory DataMart – Influenza weekly positivity by UKHSA region

Week number

North of England
South of England
London
Midlands and East of England

Proportion positive (%)
Respiratory DataMart – Respiratory syncytial virus (RSV)

- **Respiratory syncytial virus (RSV)**

![RSV Chart]

- **Positive samples**
- **% 2018/19**
- **% 2019/20**
- **% 2020/21**
- **% 2021/22**
- **% 2022/23**

**Week number**

- **Number of positive samples**
- **Proportion positive (%)**

- **Week numbers:** 27, 31, 35, 39, 43, 47, 51, 3, 7, 11, 15, 19, 23

- **Proportion positive (%) range:** 0 to 30
Respiratory DataMart weekly positivity (%) for RSV by age, England
Respiratory DataMart – Respiratory syncytial virus (RSV) weekly positivity by UKHSA region

Proportion positive (%) vs. Week number

- North of England
- South of England
- London
- Midlands and East of England
Google search queries
Normalised Google search score for COVID-19 symptoms, with weighted score for media-debiasing and historical trend, England
Flu detector
Daily estimated ILI Google search query rates per 100,000 population, England

Week number

Daily ILI estimated rate per 100,000

Baseline
2010/11
2017/18
2018/19
2019/20
2020/21
2021/22
2022/23
Secondary Care surveillance
Weekly hospital admission rate by UKHSA centre for new COVID-19 positive cases reported through SARI Watch
Weekly ICU or HDU admission rate by UKHSA centre for new COVID-19 positive cases, reported through SARI Watch

ICU or HDU admission rate per 100,000

Week number

East Midlands
East of England
London
North East
North West
South East
South West
West Midlands
Yorkshire and Humber
Weekly ICU or HDU admission rate by UKHSA centre for new influenza, reported through SARI Watch
Weekly ICU or HDU admission rate by age group for new COVID-19 positive cases, reported through SARI Watch
Weekly ICU or HDU admission rate by age group for new influenza, reported through SARI Watch
Weekly COVID-19 hospitalisation rate per 100,000 trust catchment population by age group and region, weeks 13 to 22
Rate of hospitalisation (to all levels of care including ICU-HDU) by ethnic group, per 100,000 ethnic group specific trust catchment population, England

Notes:
- This is based on data from the sentinel surveillance involving a network of spotter trusts submitting enhanced data on laboratory confirmed cases admitted to any level of care including ICU-HDU.

- From week (24 2021) the ethnicity analysis is based on a new method for assigning ethnicity, developed by UKHSA. The previous method used the most recent ethnicity recorded through linkage to Hospital Episode Statistics. However, this method led to unfeasibly high rates in the ‘Other’ ethnic group when applied to COVID-19 cases, hospitalisation or mortality. The new method uses the most frequent ethnicity recorded through linkage to Hospital Episode Statistics, unless the most frequent was ‘Other’ when the second most frequent was chosen.

- A caveat is that more recent data has under representations from London trusts, so trusts from that region are encourage to participate to strength this surveillance.
Rate of admission to ICU/HDU by ethnicity, per 100,000 trust catchment population, by month, England

Note:
- From week (24 2021) the ethnicity analysis is based on a new method for assigning ethnicity, developed by UKHSA. The previous method used the most recent ethnicity recorded through linkage to Hospital Episode Statistics. However, this method led to unfeasibly high rates in the ‘Other’ ethnic group when applied to COVID-19 cases, hospitalisation or mortality. The new method uses the most frequent ethnicity recorded through linkage to Hospital Episode Statistics, unless the most frequent was ‘Other’ when the second most frequent was chosen.

- The ICU-HDU rates prior to October 2022 were based on mandatory data i.e. acute NHS trusts were required to submit enhanced data on all cases of COVID-19 admitted to ICU-HDU ward. The mandatory requirement to submit data on COVID-19 cases admitted to ICU-HDU was discontinued in October 2022.

- From October 2022, enhanced surveillance is based on sentinel data (data reported by a network of spotter trusts). Sentinel surveillance involves reporting cases of COVID-19 admitted to all levels of care. ICU-HDU cases from sentinel surveillance data maybe too small to stratify by time and ethnicity, this is due to a smaller number of reported trusts from the sentinel scheme.
COVID-19 as primary reason for admission (Yes/No) among SARS-CoV-2 positive patient by week of admission, England, All ages

ISO Week of admission

No  Yes

0%  100%

20%  40%

40%  60%

60%  80%

80%  100%

Notes
1) Case-level sentinel surveillance data from SARI-Watch, from week 12 2020 (commencing 16 March 2020) to week 13 2023 (ending 2 April 2023) inclusive

2) Total 80,291 records in period of analysis, of which 43% (n=34,124) had COVID-19 as primary reason for admission (‘Yes’)

3) SARS-CoV-2 patients with evidence of COVID-19 treatment (antivirals or respiratory support) or COVID-19 death but have 'No' or 'Unknown' for COVID-19 as primary reason for admission (n=9,259) are reassigned to COVID-19 as primary reason of admission (‘Yes’)

4) Reassignment increases COVID-19 as primary reason for admission (‘Yes’) from 34,124 to 43,383

5) 21% (16,940/80,291) of total records in this period have missing data on the ‘Admission due to COVID-19’ indicator – these are excluded from analysis

6) Caveats: 1) London trusts under-represented since January 2021. 2) The most recent weeks are subject to retrospective updates. 3) Admissions recorded as not primarily due to COVID-19 should not be interpreted as all true incidental as there will be some with non ARI presentation due to exacerbation after recent SARS-CoV-2 infection.
Laboratory confirmed ECMO admissions (COVID-19, influenza and non-COVID-19 confirmed) to Severe Respiratory Failure centres in the UK - * SARI Watch data is provisional
SARS-CoV-2 Whole Genome Sequencing (WGS) coverage, England
Coverage of sequencing with a valid result and genotyping over time

Sequencing coverage of PCR positive tests

- Percentage sequenced
- Not sequenced
- Sequenced

Grey shading was applied to the previous 14 days to account for reporting delays in sequencing data. Cases where the individual only tested using a lateral flow device are not included in the percentage denominator.
COVID-19 vaccine uptake, England
COVID-19 vaccinations began in England on 8 December 2020 during week 50 2020 (week ending 13 December 2020). Cumulative data up to week 22 2023 (week ending 4 June 2023) was extracted from the National Immunisation Management Service (NIMS). The data presented this week is the provisional proportion of living people resident in England who had received COVID-19 vaccinations. Individuals vaccinated in England who have a registered address outside of England or where their address, age, or sex is unknown have been excluded. Due to changes in GP practice lists, in order to include newly registered patients and remove those who are no longer resident, there will be slight variation to the figures to reflect those who are currently resident in England.

Age is calculated on the date data is extracted. The weekly vaccine coverage data is extracted on a Tuesday with data capped to the previous Sunday and all backing data is updated each week going back to the start of the programme.

Data is provisional and subject to change following further validation checks. Any changes to historic figures will be reflected in the most recent publication. Please note that numbers published by UKHSA are for public health surveillance purposes only.

**Spring 2023 Campaign**

Immunity derived from vaccination declines over time, JCVI has recommended a Spring 2023 campaign with the primary objective to boost immunity in those at higher risk from COVID-19 and thereby optimise protection against severe COVID-19, specifically hospitalisation and death.

The Spring 2023 data reported below covers any booster dose administered from the 3 April 2023 provided there is at least 3 months from the previous dose. Eligible groups for the Spring campaign are defined in the COVID-19 healthcare guidance [Green Book](#) and include residents in all adults aged 75 years and over, residents in a care home for older adults, and individuals aged 5 years and over who are immunosuppressed.
**Provisional cumulative people vaccinated by age with a booster of COVID-19 vaccine from the 3 April 2023 as part of the Spring 2023 campaign in England**

<table>
<thead>
<tr>
<th>National</th>
<th>People in NIMS cohort who are living and resident in England</th>
<th>Vaccinated with an Spring booster since 3 April 2023 *</th>
<th>Percentage vaccine uptake</th>
</tr>
</thead>
<tbody>
<tr>
<td>Over 80</td>
<td>2,971,333</td>
<td>1,866,865</td>
<td>62.8</td>
</tr>
<tr>
<td>75 to under 80</td>
<td>2,435,690</td>
<td>1,465,417</td>
<td>60.2</td>
</tr>
<tr>
<td>Aged 75 and over</td>
<td>5,407,023</td>
<td>3,332,282</td>
<td>61.6</td>
</tr>
</tbody>
</table>

*Spring 2023 booster defined as any additional dose of vaccine after a 2 dose primary course provided there is an interval of at least 3 months and it is given since the 3 April 2023.

This table presents coverage as measured against the total population and includes people who are not yet due to have their Spring 2023 booster. It is important that unvaccinated individuals, especially vulnerable adults, receive a primary course of vaccination, irrespective of whether individuals have had previous infection. To understand the data in the context of vaccine waning across the whole COVID-19 programme, we present Table 8 which shows how recently a person who is living and resident in England has been vaccinated either through the primary vaccination campaign or a subsequent booster campaign.
Provisional cumulative people vaccinated by age and sex with a Spring 2023 booster of COVID-19 vaccine from the 3 April 2023 as part of the Spring campaign in England

<table>
<thead>
<tr>
<th>AGE</th>
<th>PEOPLE IN NIMS COHORT</th>
<th>MALE Vaccinated with an Spring booster since 3 April 2023 *</th>
<th>% Vaccine Uptake</th>
<th>FEMALE Vaccinated with an Spring booster since 3 April 2023 *</th>
<th>% Vaccine Uptake</th>
</tr>
</thead>
<tbody>
<tr>
<td>Over 80</td>
<td>1,229,245</td>
<td>802,672</td>
<td>65.3</td>
<td>1,740,585</td>
<td>61.1</td>
</tr>
<tr>
<td>75 to under 80</td>
<td>1,138,795</td>
<td>703,381</td>
<td>61.8</td>
<td>1,295,247</td>
<td>58.8</td>
</tr>
<tr>
<td>Aged 75 and over</td>
<td>2,368,040</td>
<td>1,506,053</td>
<td>63.6</td>
<td>3,035,832</td>
<td>60.2</td>
</tr>
</tbody>
</table>

*Spring 2023 booster defined as any additional dose of vaccine after a 2 dose primary course provided there is an interval of at least 3 months and it is given since the 3 April 2023.
Provisional cumulative people vaccinated by age with a booster of COVID-19 vaccine from the 3 April 2023 as part of the Spring campaign in England

<table>
<thead>
<tr>
<th>National</th>
<th>People in NIMS cohort who are living and resident in England</th>
<th>Vaccinated with an Spring booster since 3 April 2023 *</th>
<th>Percentage vaccine uptake</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aged over 5 years and immunosuppressed</td>
<td>2,191,442</td>
<td>724,541</td>
<td>33.1</td>
</tr>
</tbody>
</table>

*Spring 2023 booster defined as any additional dose of vaccine after a 2 dose primary course provided there is an interval of at least 3 months and it is given since the 3 April 2023.
Provisional cumulative people vaccinated with any dose of COVID-19 vaccine in the last 3 months, 3 to 6 months and vaccinated more than 6 months ago

<table>
<thead>
<tr>
<th>National</th>
<th>People in NIMS cohort who are living and resident in England</th>
<th>Vaccinated in the last 3 months (84 days)</th>
<th>Vaccinated 3 to 6 months ago (85 to 168 days)</th>
<th>Vaccinated 6 months ago (169 or more days)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Numbers vaccinated</td>
<td>Percentage vaccinated</td>
<td>Numbers vaccinated</td>
<td>Percentage vaccinated</td>
</tr>
<tr>
<td>Over 80</td>
<td>2,971,333</td>
<td>1,870,277</td>
<td>62.9</td>
<td>19,939</td>
</tr>
<tr>
<td>75 to under 80</td>
<td>2,435,690</td>
<td>1,467,630</td>
<td>60.3</td>
<td>16,538</td>
</tr>
<tr>
<td>70 to under 75</td>
<td>2,675,292</td>
<td>157,739</td>
<td>5.9</td>
<td>23,725</td>
</tr>
<tr>
<td>65 to under 70</td>
<td>3,013,056</td>
<td>102,710</td>
<td>3.4</td>
<td>32,580</td>
</tr>
<tr>
<td>60 to under 65</td>
<td>3,660,074</td>
<td>79,644</td>
<td>2.2</td>
<td>60,533</td>
</tr>
<tr>
<td>55 to under 60</td>
<td>4,128,457</td>
<td>57,699</td>
<td>1.4</td>
<td>80,113</td>
</tr>
<tr>
<td>50 to under 55</td>
<td>4,143,399</td>
<td>40,553</td>
<td>1.0</td>
<td>98,479</td>
</tr>
<tr>
<td>45 to under 50</td>
<td>3,864,089</td>
<td>24,026</td>
<td>0.6</td>
<td>39,370</td>
</tr>
<tr>
<td>40 to under 45</td>
<td>4,379,755</td>
<td>17,575</td>
<td>0.4</td>
<td>32,918</td>
</tr>
<tr>
<td>35 to under 40</td>
<td>4,685,205</td>
<td>12,886</td>
<td>0.3</td>
<td>30,604</td>
</tr>
<tr>
<td>30 to under 35</td>
<td>4,784,659</td>
<td>10,242</td>
<td>0.2</td>
<td>29,000</td>
</tr>
<tr>
<td>25 to under 30</td>
<td>4,412,979</td>
<td>7,752</td>
<td>0.2</td>
<td>23,922</td>
</tr>
<tr>
<td>20 to under 25</td>
<td>3,809,139</td>
<td>5,494</td>
<td>0.1</td>
<td>18,634</td>
</tr>
<tr>
<td>18 to under 20</td>
<td>1,400,276</td>
<td>2,941</td>
<td>0.2</td>
<td>9,963</td>
</tr>
<tr>
<td>16 to under 18</td>
<td>1,420,334</td>
<td>2,458</td>
<td>0.2</td>
<td>15,576</td>
</tr>
<tr>
<td>12 to under 16</td>
<td>2,983,164</td>
<td>6,474</td>
<td>0.2</td>
<td>21,652</td>
</tr>
<tr>
<td>5 to under 12</td>
<td>5,007,221</td>
<td>9,312</td>
<td>0.2</td>
<td>31,676</td>
</tr>
</tbody>
</table>

This table is presented to provide an overview of how recently a person has been vaccinated either through the primary vaccination campaign or subsequent booster campaigns. This helps us understand the data in the context of vaccine waning across the whole COVID-19 programme. Breakdowns by Ethnicity, and IMD, for those aged 75 and over can be found in the backing tables.
Provisional cumulative people vaccinated with any dose of COVID-19 vaccine in the last 3 months, 3 to 6 months and vaccinated more than 6 months ago

- Not vaccinated
- vaccinated 3-6 months ago (85-168 days)
- vaccinated 6 months ago (169+ days)
- vaccinated in the last 3 months (84 days)

Number of people

Over 80
75 to under 80
70 to under 75
65 to under 70
60 to under 65
55 to under 60
50 to under 55
45 to under 50
40 to under 45
35 to under 40
30 to under 35
25 to under 30
20 to under 25
18 to under 20
16 to under 18
12 to under 16
5 to under 12

Number of people
Provisional cumulative people vaccinated with any dose of COVID-19 vaccine in the last 3 months, 3 to 6 months and vaccinated more than 6 months ago by ethnicity in those living and resident in England, aged 75 and over.

- **Not Vaccinated**
- **Vaccinated 6 months ago**
- **Vaccinated 3 to 6 months ago**
- **Vaccinated in the last 3 months**
Provisional cumulative people vaccinated with any dose of COVID-19 vaccine in the last 3 months, 3 to 6 months and vaccinated more than 6 months ago by indices of multiple deprivation (IMD)* in those living and resident in England, aged 75 and over

*Decile 1 represents the most deprived 10% (or decile) of small areas in England and Decile 10 represents the least deprived 10% (or decile) of small areas in England.
For a regional breakdown of the ethnicity data, please see the data file that accompanies this report.

The immunosuppressed group has been updated to include a wider cohort who are eligible for vaccination and therefore is not comparable to data previously used in this report. Detailed information on the NHS Digital characterisation of the immunosuppressed group can be found on the NHSDigital website, including explanation of the previous definition.

For COVID-19 data on the real-world effectiveness of the COVID-19 vaccines, and on COVID-19 vaccination in pregnancy, please see the COVID-19 vaccine surveillance reports.

For COVID-19 management information on the number of COVID-19 vaccinations provided by the NHS in England, please see the COVID-19 vaccinations webpage.

For UK COVID-19 daily vaccination figures and definitions, please see the Vaccinations’ section of the UK COVID-19 dashboard.

The population coverage data representing the evergreen offer of doses 1, 2, and 3 has changed little in recent months and are no longer presented in both the UKHSA weekly flu and COVID-19 surveillance reports and in the UK COVID-19 Dashboard. Both the UKHSA weekly flu and COVID-19 surveillance reports and in the UK COVID-19 Dashboard now highlight data on the most recent vaccination campaign in those at higher risk from COVID-19 as immunity derived from vaccination declines over time. The overall vaccine uptake in the living and resident population for those with at least dose 1, 2 and 3 doses is still available within the backing tables for this section and in the dashboard APIs.